(Q34635446)

3 August 2017

1 reference

title

beta(3)-Adrenoceptor agonists: potential, pitfalls and progress (English)

1 reference

3 August 2017

Jonathan R S Arch

1

1 reference

3 August 2017

language of work or name

English

0 references

publication date

1 April 2002

1 reference

European Journal of Pharmacology

3 August 2017

published in

1 reference

3 August 2017

volume

440

1 reference

3 August 2017

issue

2-3

1 reference

3 August 2017

page(s)

99-107

1 reference

Meta-analysis of the association of the Trp64Arg polymorphism in the beta3 adrenergic receptor with body mass index

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901421-8

The beta 3-adrenergic system and beta 3-adrenergic agonists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901421-8

Beta 3 and atypical beta-adrenoceptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901421-8

Atypical β-adrenoceptor on brown adipocytes as target for anti-obesity drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901421-8

Chronic administration of BRL 26830A for 9 weeks improves insulin sensitivity but does not prevent weight gain in gold-thioglucose obese mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901421-8

BRL 35135, a potent and selective atypical beta-adrenoceptor agonist

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901421-8

The tissue distribution of the human beta3-adrenoceptor studied using a monoclonal antibody: direct evidence of the beta3-adrenoceptor in human adipose tissue, atrium and skeletal muscle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901421-8

Anti-obesity drugs: a critical review of current therapies and future opportunities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901421-8

Binding, gating, affinity and efficacy: the interpretation of structure-activity relationships for agonists and of the effects of mutating receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901421-8

Beta3-adrenergic agonists: potential therapeutics for obesity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901421-8

Factors influencing the composition of the weight lost by obese patients on a reducing diet

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901421-8

Molecular characterization of the human beta 3-adrenergic receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901421-8

A selective human beta3 adrenergic receptor agonist increases metabolic rate in rhesus monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901421-8

Nonshivering thermogenesis in the rat. II. Measurements of blood flow with microspheres point to brown adipose tissue as the dominant site of the calorigenesis induced by noradrenaline

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901421-8

Meta-analysis of the association of Trp64Arg polymorphism of beta 3-adrenergic receptor gene with body mass index

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901421-8

Lipolytic effects of conventional beta 3-adrenoceptor agonists and of CGP 12,177 in rat and human fat cells: preliminary pharmacological evidence for a putative beta 4-adrenoceptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901421-8

STUDIES ON THE RELATION BETWEEN MOBILIZATION OF FREE FATTY ACIDS AND ENERGY METABOLISM IN MAN: EFFECTS OF NOREPINEPHRINE AND NICOTINIC ACID.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901421-8

Polymorphism of the human beta3-adrenoceptor gene forms a well-conserved haplotype that is associated with moderate obesity and altered receptor function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901421-8

Protein kinase C activation: isozyme-specific effects on metabolism and cardiovascular complications in diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901421-8

Functional and molecular biological evidence for a possible beta3-adrenoceptor in the human detrusor muscle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901421-8

Mice expressing human but not murine beta3-adrenergic receptors under the control of human gene regulatory elements.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901421-8

Four beta-adrenoceptor subtypes in the mammalian heart

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901421-8

Differences between the third cardiac beta-adrenoceptor and the colonic beta 3-adrenoceptor in the rat.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901421-8

Abolition of (-)-CGP 12177-evoked cardiostimulation in double beta1/beta2-adrenoceptor knockout mice. Obligatory role of beta1-adrenoceptors for putative beta4-adrenoceptor pharmacology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901421-8

The relative contribution of affinity and efficacy to agonist activity: organ selectivity of noradrenaline and oxymetazoline with reference to the classification of drug receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901421-8

Anti-obesity and anti-diabetic activities of a new beta3 adrenergic receptor agonist, (S)-(Z)-[4-[[1-[2-[(2-hydroxy-3-phenoxypropyl)]amino]ethyl]-1-propenyl] phenoxy] acetic acid ethanedioic acid (SWR-0342SA), in KK-Ay mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901421-8

A risk-benefit assessment of anti-obesity drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901421-8

Desensitization and resensitization of beta 1- and putative beta 4-adrenoceptor mediated responses occur in parallel in a rat model of cardiac failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901421-8

Assessment of beta 2- and beta 3-adrenoceptors in rat white adipose tissues by radioligand binding assay

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901421-8

Development of obesity in transgenic mice after genetic ablation of brown adipose tissue

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901421-8

Functional identification of rat atypical beta-adrenoceptors by the first beta 3-selective antagonists, aryloxypropanolaminotetralins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901421-8

Discovery of a potent, orally bioavailable beta(3) adrenergic receptor agonist, (R)-N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-[4 -[4-(trifluoromethyl)phenyl]thiazol-2-yl]benzenesulfonamide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901421-8

Pharmacological characteristics and species-related variations of beta 3-adrenergic receptors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901421-8

Inhibition of lipolysis reduces beta1-adrenoceptor-mediated thermogenesis in man

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901421-8

In vivo beta3-adrenergic stimulation of human thermogenesis and lipid use

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901421-8

Differences between the effects of noradrenaline and the beta-adrenoceptor agonist BRL 28410 in brown adipose tissue and hind limb of the anaesthetized rat

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901421-8

Anti-obesity and anti-diabetic effects of CL316,243, a highly specific beta 3-adrenoceptor agonist, in Otsuka Long-Evans Tokushima Fatty rats: induction of uncoupling protein and activation of glucose transporter 4 in white fat

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901421-8

Trp64Arg mutation of beta3-adrenoceptor gene deteriorates lipolysis induced by beta3-adrenoceptor agonist in human omental adipocytes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901421-8

Increase in insulin action and fat oxidation after treatment with CL 316,243, a highly selective beta3-adrenoceptor agonist in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901421-8

Sustained improvement in glucose homeostasis in lean and obese mice following chronic administration of the beta 3 agonist SR 58611A.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2802%2901421-8

10.1016/S0014-2999(02)01421-8

7 January 2021

Identifiers

DOI

1 reference

3 August 2017

1 reference